Based on the key indicators related to Salarius Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Salarius Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Salarius Pharmaceuticals' Other Current Liabilities is fairly stable compared to the past year. Total Current Liabilities is likely to rise to about 2.3 M in 2025, whereas Total Assets are likely to drop slightly above 5.6 M in 2025. Key indicators impacting Salarius Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Salarius Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Salarius Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Salarius Pharmaceuticals.
Please note, the imprecision that can be found in Salarius Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Salarius Pharmaceuticals. Check Salarius Pharmaceuticals' Beneish M Score to see the likelihood of Salarius Pharmaceuticals' management manipulating its earnings.
Salarius Pharmaceuticals Stock Summary
Salarius Pharmaceuticals competes with Akari Therapeutics, Nutriband, SAB Biotherapeutics, GeoVax Labs, and Corvus Pharmaceuticals. Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. Salarius Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Salarius Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Salarius Pharmaceuticals. It measures of how well Salarius is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Salarius Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Salarius had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Salarius Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Salarius Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Salarius Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Salarius Pharmaceuticals competition to find correlations between indicators driving Salarius Pharmaceuticals's intrinsic value. More Info.
Salarius Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Salarius Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Salarius Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Salarius Pharmaceuticals Systematic Risk
Salarius Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Salarius Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Salarius Pharmaceuticals correlated with the market. If Beta is less than 0 Salarius Pharmaceuticals generally moves in the opposite direction as compared to the market. If Salarius Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Salarius Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Salarius Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Salarius Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Salarius Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Salarius Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Salarius Pharmaceuticals growth as a starting point in their analysis.
Salarius Pharmaceuticals March 1, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Salarius Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Salarius Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Salarius Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Salarius Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Salarius Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.